Outcomes of pregnancy during interferon beta-1a therapy in Japanese patients with multiple sclerosis: Interim results of a postmarketing surveillance study

Yuko Shimizu, Haruki Makioka, Naozumi Harada, Shoko Nakabayashi, Takahiko Saida, Jun-Ichi Kira

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objectives To evaluate pregnancy outcomes in Japanese patients with multiple sclerosis (MS) enrolled in a postmarketing surveillance study of intramuscular interferon beta-1a (IM IFN beta-1a). Methods Safety data were collected from Japanese patients receiving 30 μg weekly IM IFN beta-1a. Pregnancy outcomes and annualized relapse rates (ARR) were analyzed retrospectively in patients who registered into the postmarketing surveillance study. Results A total of 1110 of 1638 patients registered in the postmarketing surveillance study were women. A total of 21 pregnancies (20 patients) resulted in 17 live births, 2 induced abortions, one spontaneous abortion and one unknown outcome. Weights and lengths of the 17 newborns were similar to newborns in the general Japanese population. No complications or malformations were reported. Of these 20 patients, nine experienced relapses in the year after childbirth, two experienced relapses in the year before pregnancy, and one experienced relapses before and during pregnancy. The mean (standard deviation) ARR was 0.94 (2.18) in the year before pregnancy, 0.25 (1.00), 0 (0) and 0 (0) in the three trimesters of pregnancy, and 1.05 (1.81), 0.84 (1.68), 0.63 (2.01) and 0.21 (0.92) in the first four quarters postpartum. Of the five patients who relapsed during the first quarter postpartum, only one had resumed IFN beta-1a treatment for 35 days. Conclusions Although sample size limits our ability to draw definitive conclusions, we did not find evidence that IFN beta-1a has adverse effects on pregnancy outcomes in Japanese patients with MS. Early IFN beta-1a resumption might reduce the risk of relapse within the first quarter postpartum.

Original languageEnglish
Pages (from-to)402-408
Number of pages7
JournalClinical and Experimental Neuroimmunology
Volume6
Issue number4
DOIs
Publication statusPublished - Nov 1 2015

Fingerprint

Pregnancy Outcome
Multiple Sclerosis
Recurrence
Postpartum Period
Pregnancy
Therapeutics
Newborn Infant
Pregnancy Trimesters
Interferon beta-1a
Induced Abortion
Live Birth
Spontaneous Abortion
Sample Size
Parturition
Safety
Weights and Measures
Population

All Science Journal Classification (ASJC) codes

  • Neuroscience (miscellaneous)
  • Immunology
  • Immunology and Microbiology (miscellaneous)
  • Clinical Neurology

Cite this

Outcomes of pregnancy during interferon beta-1a therapy in Japanese patients with multiple sclerosis : Interim results of a postmarketing surveillance study. / Shimizu, Yuko; Makioka, Haruki; Harada, Naozumi; Nakabayashi, Shoko; Saida, Takahiko; Kira, Jun-Ichi.

In: Clinical and Experimental Neuroimmunology, Vol. 6, No. 4, 01.11.2015, p. 402-408.

Research output: Contribution to journalArticle

@article{c5b7cfc0e8d34c949efffbc1680a516d,
title = "Outcomes of pregnancy during interferon beta-1a therapy in Japanese patients with multiple sclerosis: Interim results of a postmarketing surveillance study",
abstract = "Objectives To evaluate pregnancy outcomes in Japanese patients with multiple sclerosis (MS) enrolled in a postmarketing surveillance study of intramuscular interferon beta-1a (IM IFN beta-1a). Methods Safety data were collected from Japanese patients receiving 30 μg weekly IM IFN beta-1a. Pregnancy outcomes and annualized relapse rates (ARR) were analyzed retrospectively in patients who registered into the postmarketing surveillance study. Results A total of 1110 of 1638 patients registered in the postmarketing surveillance study were women. A total of 21 pregnancies (20 patients) resulted in 17 live births, 2 induced abortions, one spontaneous abortion and one unknown outcome. Weights and lengths of the 17 newborns were similar to newborns in the general Japanese population. No complications or malformations were reported. Of these 20 patients, nine experienced relapses in the year after childbirth, two experienced relapses in the year before pregnancy, and one experienced relapses before and during pregnancy. The mean (standard deviation) ARR was 0.94 (2.18) in the year before pregnancy, 0.25 (1.00), 0 (0) and 0 (0) in the three trimesters of pregnancy, and 1.05 (1.81), 0.84 (1.68), 0.63 (2.01) and 0.21 (0.92) in the first four quarters postpartum. Of the five patients who relapsed during the first quarter postpartum, only one had resumed IFN beta-1a treatment for 35 days. Conclusions Although sample size limits our ability to draw definitive conclusions, we did not find evidence that IFN beta-1a has adverse effects on pregnancy outcomes in Japanese patients with MS. Early IFN beta-1a resumption might reduce the risk of relapse within the first quarter postpartum.",
author = "Yuko Shimizu and Haruki Makioka and Naozumi Harada and Shoko Nakabayashi and Takahiko Saida and Jun-Ichi Kira",
year = "2015",
month = "11",
day = "1",
doi = "10.1111/cen3.12231",
language = "English",
volume = "6",
pages = "402--408",
journal = "Clinical and Experimental Neuroimmunology",
issn = "1759-1961",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Outcomes of pregnancy during interferon beta-1a therapy in Japanese patients with multiple sclerosis

T2 - Interim results of a postmarketing surveillance study

AU - Shimizu, Yuko

AU - Makioka, Haruki

AU - Harada, Naozumi

AU - Nakabayashi, Shoko

AU - Saida, Takahiko

AU - Kira, Jun-Ichi

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Objectives To evaluate pregnancy outcomes in Japanese patients with multiple sclerosis (MS) enrolled in a postmarketing surveillance study of intramuscular interferon beta-1a (IM IFN beta-1a). Methods Safety data were collected from Japanese patients receiving 30 μg weekly IM IFN beta-1a. Pregnancy outcomes and annualized relapse rates (ARR) were analyzed retrospectively in patients who registered into the postmarketing surveillance study. Results A total of 1110 of 1638 patients registered in the postmarketing surveillance study were women. A total of 21 pregnancies (20 patients) resulted in 17 live births, 2 induced abortions, one spontaneous abortion and one unknown outcome. Weights and lengths of the 17 newborns were similar to newborns in the general Japanese population. No complications or malformations were reported. Of these 20 patients, nine experienced relapses in the year after childbirth, two experienced relapses in the year before pregnancy, and one experienced relapses before and during pregnancy. The mean (standard deviation) ARR was 0.94 (2.18) in the year before pregnancy, 0.25 (1.00), 0 (0) and 0 (0) in the three trimesters of pregnancy, and 1.05 (1.81), 0.84 (1.68), 0.63 (2.01) and 0.21 (0.92) in the first four quarters postpartum. Of the five patients who relapsed during the first quarter postpartum, only one had resumed IFN beta-1a treatment for 35 days. Conclusions Although sample size limits our ability to draw definitive conclusions, we did not find evidence that IFN beta-1a has adverse effects on pregnancy outcomes in Japanese patients with MS. Early IFN beta-1a resumption might reduce the risk of relapse within the first quarter postpartum.

AB - Objectives To evaluate pregnancy outcomes in Japanese patients with multiple sclerosis (MS) enrolled in a postmarketing surveillance study of intramuscular interferon beta-1a (IM IFN beta-1a). Methods Safety data were collected from Japanese patients receiving 30 μg weekly IM IFN beta-1a. Pregnancy outcomes and annualized relapse rates (ARR) were analyzed retrospectively in patients who registered into the postmarketing surveillance study. Results A total of 1110 of 1638 patients registered in the postmarketing surveillance study were women. A total of 21 pregnancies (20 patients) resulted in 17 live births, 2 induced abortions, one spontaneous abortion and one unknown outcome. Weights and lengths of the 17 newborns were similar to newborns in the general Japanese population. No complications or malformations were reported. Of these 20 patients, nine experienced relapses in the year after childbirth, two experienced relapses in the year before pregnancy, and one experienced relapses before and during pregnancy. The mean (standard deviation) ARR was 0.94 (2.18) in the year before pregnancy, 0.25 (1.00), 0 (0) and 0 (0) in the three trimesters of pregnancy, and 1.05 (1.81), 0.84 (1.68), 0.63 (2.01) and 0.21 (0.92) in the first four quarters postpartum. Of the five patients who relapsed during the first quarter postpartum, only one had resumed IFN beta-1a treatment for 35 days. Conclusions Although sample size limits our ability to draw definitive conclusions, we did not find evidence that IFN beta-1a has adverse effects on pregnancy outcomes in Japanese patients with MS. Early IFN beta-1a resumption might reduce the risk of relapse within the first quarter postpartum.

UR - http://www.scopus.com/inward/record.url?scp=84954474011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954474011&partnerID=8YFLogxK

U2 - 10.1111/cen3.12231

DO - 10.1111/cen3.12231

M3 - Article

AN - SCOPUS:84954474011

VL - 6

SP - 402

EP - 408

JO - Clinical and Experimental Neuroimmunology

JF - Clinical and Experimental Neuroimmunology

SN - 1759-1961

IS - 4

ER -